| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥4.23B | ¥4.58B | -7.6% |
| Cost of Sales | ¥1.87B | ¥1.86B | +0.2% |
| Gross Profit | ¥2.36B | ¥2.71B | -13.0% |
| SG&A Expenses | ¥2.04B | ¥1.99B | +2.4% |
| Operating Income | ¥324M | ¥726M | -55.4% |
| Non-operating Income | ¥29M | ¥36M | -19.4% |
| Non-operating Expenses | ¥29M | ¥57M | -49.1% |
| Ordinary Income | ¥325M | ¥705M | -53.9% |
| Profit Before Tax | ¥821M | ¥673M | +22.0% |
| Income Tax Expense | ¥151M | ¥-41M | +468.3% |
| Net Income | ¥669M | ¥714M | -6.3% |
| Net Income Attributable to Owners | ¥669M | ¥714M | -6.3% |
| Total Comprehensive Income | ¥255M | ¥1.25B | -79.6% |
| Interest Expense | ¥4M | ¥6M | -33.3% |
| Earnings per Unit (EPU) | ¥13.33 | ¥14.24 | -6.4% |
| Distribution per Unit (DPU) | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥8.19B | ¥8.76B | ¥-571M |
| Cash and Deposits | ¥3.79B | ¥4.53B | ¥-744M |
| Accounts Receivable | ¥2.02B | ¥2.43B | ¥-408M |
| Inventories | ¥637M | ¥452M | +¥185M |
| Non-current Assets | ¥3.69B | ¥4.15B | ¥-458M |
| Item | Value |
|---|---|
| Net Profit Margin | 15.8% |
| Gross Profit Margin | 55.8% |
| Current Ratio | 352.9% |
| Quick Ratio | 325.4% |
| Debt-to-Equity Ratio | 0.44x |
| Interest Coverage Ratio | 81.00x |
| Effective Tax Rate | 18.4% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -7.6% |
| Operating Income YoY Change | -55.3% |
| Ordinary Income YoY Change | -53.9% |
| Net Income Attributable to Owners YoY Change | -6.3% |
| Total Comprehensive Income YoY Change | -79.5% |
| Item | Value |
|---|---|
| Units Outstanding (incl. Treasury) | 50.64M shares |
| Treasury Units | 386K shares |
| Average Units Outstanding | 50.23M shares |
| NAV per Unit | ¥163.90 |
| Item | Amount |
|---|---|
| Q2 Distribution | ¥0.00 |
| Year-End Distribution | ¥0.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| InfectionControl | ¥390M | ¥-143M |
| OtherBusinessLines | ¥4M | ¥-12M |
| Pharmaceuticals | ¥3.83B | ¥1.09B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥6.30B |
| Operating Income Forecast | ¥300M |
| Ordinary Income Forecast | ¥300M |
| Net Income Attributable to Owners Forecast | ¥580M |
| Earnings per Unit Forecast (EPU) | ¥11.54 |
| Property, Plant & Equipment | ¥3.31B | ¥3.27B | +¥34M |
| Intangible Assets | ¥25M | ¥27M | ¥-2M |
| Investment Securities | ¥0 | ¥461M | ¥-461M |
| Total Assets | ¥11.88B | ¥12.91B | ¥-1.03B |
| Current Liabilities | ¥2.32B | ¥2.85B | ¥-534M |
| Accounts Payable | ¥334M | ¥338M | ¥-4M |
| Non-current Liabilities | ¥1.33B | ¥2.09B | ¥-768M |
| Long-term Loans | ¥27M | ¥792M | ¥-765M |
| Total Liabilities | ¥3.65B | ¥4.95B | ¥-1.30B |
| Total Equity | ¥8.24B | ¥7.96B | +¥272M |
| Capital Stock | ¥10M | ¥10M | ¥0 |
| Capital Surplus | ¥4.98B | ¥5.00B | ¥-19M |
| Retained Earnings | ¥3.20B | ¥2.53B | +¥670M |
| Treasury Stock | ¥-237M | ¥-273M | +¥36M |
| Owners' Equity | ¥8.24B | ¥7.96B | +¥272M |
| Working Capital | ¥5.87B | - | - |